Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Akeso builds on earlier success with bispecifics
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
Like Merck, Bristol goes to China
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
ASH 2023 – the markets forgive MorphoSys
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.